Search results
Keeping an Eye on Abbvie Inc
Knox Daily· 18 hours agoAbbvie Inc’s recently made public that its EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas unloaded Company’s shares for reported $3.72 million on Mar 20 ’24. In the deal valued ...
Michael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks By Investing.com
Investing.com· 4 days agoMichael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks
3 Reasons to Buy AbbVie Stock on the Dip
Motley Fool via Yahoo Finance· 2 days agoIt's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this...
AbbVie to Present at the Bank of America Securities Healthcare Conference
FOX 4 Kansas City· 1 day agoReents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical ...
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 4 days agoAbbVie's acquisition of ImmunoGen strengthens its oncology pipeline and solid tumor capabilities. Robust financial performance with $12.3 billion in net...
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks via Yahoo Finance· 6 days agoAbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 6 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
AbbVie Inc Stock Price Today | BVMF ABBV34 - Investing.com Canada
Investing.com· 1 day agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 6 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 7 days agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. AbbVie
